EP1429786A1 - Contraceptifs d-mannose - Google Patents

Contraceptifs d-mannose

Info

Publication number
EP1429786A1
EP1429786A1 EP02759484A EP02759484A EP1429786A1 EP 1429786 A1 EP1429786 A1 EP 1429786A1 EP 02759484 A EP02759484 A EP 02759484A EP 02759484 A EP02759484 A EP 02759484A EP 1429786 A1 EP1429786 A1 EP 1429786A1
Authority
EP
European Patent Office
Prior art keywords
mannose
contraceptive
female
sperm
egg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP02759484A
Other languages
German (de)
English (en)
Other versions
EP1429786A4 (fr
EP1429786B1 (fr
Inventor
Dale L. Benedict
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Tech Pharmacal Inc
Original Assignee
Benedict Dale L
Bio Tech Pharmacal Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benedict Dale L, Bio Tech Pharmacal Inc filed Critical Benedict Dale L
Publication of EP1429786A1 publication Critical patent/EP1429786A1/fr
Publication of EP1429786A4 publication Critical patent/EP1429786A4/fr
Application granted granted Critical
Publication of EP1429786B1 publication Critical patent/EP1429786B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Definitions

  • the present invention relates to the use of D-Mannose to inhibit or prevent the uniting of a sperm and egg in conception.
  • the presence of excess mannose in a reproductive system inhibits sperm capacitation.
  • D-Mannose has been widely used in the feed industry to treat and prevent urinary tract infections by inhibiting the adherence of bacteria to membranes or cell walls. Interactions between proteins and D-Mannose in the acrosome of mice, rats, horses chickens humans and other animals, appear to be related to adherence of the sperm to the egg. Various studies have been performed, some indicating that D-Mannose causes greater adherence of sperm acrosome to eggs and others that it causes less adherence. In any case, the present invention involves the inhibition of conception while also preventing or alleviating urinary tract infections or cystitis.
  • silica is well known to those skilled in the art to prevent D-Mannose from compacting upon exposure to moisture. Thus silica is useful to mix with D-Mannose powder prior to encapsulation.
  • the present invention involves oral administration, preferably in capsule form, of D-Mannose to a female with the possibility of sexual intercourse in the near future.
  • One preferable dosage for an average adult female human would involve the ingestion of about three (3) capsules, each containing about 420 milligrams of D-Mannose about every two (2) hours beginning about a day before intercourse. This may be reduced to about 2-3 of such capsules about one hour before intercourse and about the same dosage about one hour after.
  • the oral spray of a D-Mannose solution may also be used. Such dosages and timing may vary to a significant extent to be most effective.
  • the useful dose for an average adult female human would range from about 1 gram to about 10 grams of D-Mannose per day.
  • Useful doses for other animals can be determined by scaling the relative to the other animal's weight relative to average adult female humans.
  • the administration of D-Mannose to domestic or wild animals may be done to inhibit animal population growth. Such administration may be in water, salt or foods.
  • D-Mannose may be utilized simply as a powder addition to drinks or foods.
  • the dosages could be supplemented or replaced by a mannose-containing contraceptive jelly, douche or intravaginal cream, or the like. What is important is for the subject woman to gain an internal concentration of mannose efficient to inhibit the fertilizing interaction of sperm with the egg.
  • the present invention involves the successful inhibition of sperm-egg interaction to prevent or reduce the likelihood of conception by the presence of a sufficient quality of D-Mannose. It is believed that D-Mannose binds to sites on the sperm which are used by the sperm in its interaction with the egg in a way in which common table sugar, sucrose, and most other commonly used sugars do not. While D- Mannose is most preferably used in capsules, tablets or powders may also be used. Douches containing D-Mannose may be used alone or in combination with oral D-Mannose to inhibit effective sperm egg interaction.
  • D-Mannose dosages are also usable to enhance the effectiveness of other contraceptive methods such as condoms, diaphragms, hormonal pills, etc.
  • D-Mannose may be supplied vaginally with a diaphragm, or a condom that contains D-Mannose. It may be supplied taken with separate hormonal pills or in pills which are combined with hormonal pills.
  • D-Mannose douches or intervaginal creams are effective means of delivering the D-Mannose particularly if used within one day before or soon after intercourse. The closer in time to the intercourse the vaginal applications are made, the more effective the application. Women of child-bearing/age not desiring to become pregnant should take a constant maintenance dose of D-Mannose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02759484A 2001-08-29 2002-08-29 Contraceptifs d-mannose Expired - Lifetime EP1429786B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31566101P 2001-08-29 2001-08-29
US315661P 2001-08-29
PCT/US2002/027463 WO2003020288A1 (fr) 2001-08-29 2002-08-29 Contraceptifs d-mannose

Publications (3)

Publication Number Publication Date
EP1429786A1 true EP1429786A1 (fr) 2004-06-23
EP1429786A4 EP1429786A4 (fr) 2005-12-14
EP1429786B1 EP1429786B1 (fr) 2012-02-08

Family

ID=23225485

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02759484A Expired - Lifetime EP1429786B1 (fr) 2001-08-29 2002-08-29 Contraceptifs d-mannose

Country Status (10)

Country Link
US (2) US6753319B2 (fr)
EP (1) EP1429786B1 (fr)
CN (1) CN1578666A (fr)
AT (1) ATE544456T1 (fr)
AU (1) AU2002324816B2 (fr)
CA (1) CA2506944C (fr)
ES (1) ES2382242T3 (fr)
MX (1) MXPA04002950A (fr)
NZ (1) NZ532004A (fr)
WO (1) WO2003020288A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002950A (es) * 2001-08-29 2005-04-11 Biotech Pharmacal Inc Anticonceptivos de d-manosa.
US20050020510A1 (en) * 2002-08-29 2005-01-27 Benedict Dale L. D-mannose contraceptives
US20040147459A1 (en) * 2002-10-23 2004-07-29 Joseph Oneal Method and composition for maintaining urinary tract health in the face of infections
JP4488852B2 (ja) * 2004-09-17 2010-06-23 味の素ゼネラルフーヅ株式会社 体内脂肪低減作用を有する組成物
WO2007086100A1 (fr) * 2006-01-24 2007-08-02 Ajinomoto General Foods, Inc. Composition ayant un effet d'abaissement de la pression sanguine et/ou d'inhibition de l'augmentation de la pression sanguine, et aliment et boisson la contenant
US8063026B2 (en) * 2006-04-06 2011-11-22 Richard Katz Method of palliating lower urinary tract infections by treatment with mannan oligosaccharides
JP4771882B2 (ja) * 2006-07-21 2011-09-14 味の素ゼネラルフーヅ株式会社 糖尿病または糖尿病性合併症の治療、予防、または改善作用を有する組成物およびこれを含有する飲料
US20220105032A1 (en) * 2020-10-07 2022-04-07 Uqora, Inc. Beverage unit and method to provide the beverage unit

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984004457A1 (fr) * 1983-05-16 1984-11-22 University Patents Inc Contraceptif contenant de l'alpha-lactalbumine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04334320A (ja) * 1991-05-10 1992-11-20 Nakano Vinegar Co Ltd 整腸効果作用組成物
US5994086A (en) * 1994-03-30 1999-11-30 North Shore University Hospital Method for assessing infertility by binding of mannose to sperm cells
US5854254A (en) 1994-03-30 1998-12-29 North Shore University Hospital Male contraceptives
US5939279A (en) * 1997-09-18 1999-08-17 The Board Of Trustees Of The University Of Arkansas Inhibition of bacterial binding by high-mannose oligosaccharides
MXPA04002950A (es) * 2001-08-29 2005-04-11 Biotech Pharmacal Inc Anticonceptivos de d-manosa.
US20050020510A1 (en) * 2002-08-29 2005-01-27 Benedict Dale L. D-mannose contraceptives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984004457A1 (fr) * 1983-05-16 1984-11-22 University Patents Inc Contraceptif contenant de l'alpha-lactalbumine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch, Week 199301 Derwent Publications Ltd., London, GB; Class B03, AN 1993-005498 XP002350115 & JP 04 334320 A (NAKAN SUMESE KK) 20 November 1992 (1992-11-20) *
See also references of WO03020288A1 *
SHALGI R; MATITYAHU A; NEBEL L: "The Role of Carbohydrates in Sperm-Egg Interaction in Rats" BIOLOGY OF REPRODUCTION, vol. 34, no. 3, 1986, pages 446-452, XP002350108 *
YOSHIDA-KOMIYA H; TULSIANI D R P; HIRAYAMA T; ARAKI Y: "Mannose-binding molecules of rat spermatozoa and sperm-egg interaction" ZYGOTE, vol. 7, no. 4, November 1999 (1999-11), pages 335-346, XP009055676 *

Also Published As

Publication number Publication date
ES2382242T3 (es) 2012-06-06
US20030073643A1 (en) 2003-04-17
MXPA04002950A (es) 2005-04-11
EP1429786A4 (fr) 2005-12-14
US20040180839A1 (en) 2004-09-16
CN1578666A (zh) 2005-02-09
EP1429786B1 (fr) 2012-02-08
CA2506944C (fr) 2010-10-12
WO2003020288A1 (fr) 2003-03-13
CA2506944A1 (fr) 2003-03-13
NZ532004A (en) 2006-06-30
AU2002324816B2 (en) 2009-09-17
US6753319B2 (en) 2004-06-22
ATE544456T1 (de) 2012-02-15

Similar Documents

Publication Publication Date Title
RU2139056C1 (ru) Гормональная заместительная терапия
US20090105161A1 (en) D-mannose contraceptives
Amaral et al. Study of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gel
KR100908161B1 (ko) 응급피임용 투약방법 및 약제학적 조성물
CZ286202B6 (cs) Farmaceutický přípravek
US6753319B2 (en) D-mannose contraceptives
AU2002324816A1 (en) D-Mannose Contraceptives
Portugal et al. Effects of chronic melengestrol acetate contraceptive treatment on perineal tumescence, body weight, and sociosexual behavior of hamadryas baboons (Papio hamadryas)
US10835564B2 (en) Composition for preventing and treating premature ovarian failure, containing Evodia rutaecarpa bentham extract having protective activity against ovotoxicity
US6555140B1 (en) Composition and method for enhancing male fertility and libido
EP2440213B1 (fr) Utilisation d'1,25-dihydroxyvitamine D3 glycosides chez des animaux producteurs de lait
Goettsch et al. α-Tocopherol Requirement of the Rat for Reproduction in the Female and Prevention of Muscular Dystrophy in the Young
Jensen et al. Deposition pattern of the antifertility agent, gossypol, in selected organs of male rats
RU2517061C1 (ru) Способ лечения мужского бесплодия, обусловленного аутоиммунными реакциями против сперматозоидов
TW201420103A (zh) 包含左炔諾孕酮（ｌｅｖｏｎｏｒｇｅｓｔｒｅｌ）及ｃｏｘ抑制劑之醫藥組合物於「依需求（ｏｎ ｄｅｍａｎｄ）」避孕之用途及應用療法
Einer-Jensen et al. Diminished weight of rat foetuses after treatment of pregnant rats with haloperidol
US4252798A (en) Reversible male contraception
Nabi et al. An update on male contraception
Chow et al. Induction of premature birth in rats by a methionine antagonist
US9539228B2 (en) Composition containing lysine as a nutritional supplement or treatment in the case of herpes
RU2519226C1 (ru) Средство для профилактики и лечения андрологических заболеваний и способ его получения
EP1173185A1 (fr) Medicament augmentant la fertilite et ameliorant le developpement foetal
Bromberg et al. Implantation of riboflavin pellets in animals and man
GB2165452A (en) Weight control in human and non-human animals
INDEX Glaxo Mpy to.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040325

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20051028

17Q First examination report despatched

Effective date: 20061004

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BENEDICT, DALE L.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIO-TECH PHARMACAL, INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BENEDICT, MARTHA

Inventor name: BENEDICT, DALE L.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 60242180

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031700000

Ipc: A61K0031700400

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/70 20060101ALI20110809BHEP

Ipc: A61K 31/702 20060101ALI20110809BHEP

Ipc: A61K 31/7004 20060101AFI20110809BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 544456

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60242180

Country of ref document: DE

Effective date: 20120405

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20120208

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2382242

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20120606

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120608

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120208

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120509

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120208

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 544456

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120208

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120208

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120208

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120208

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20121109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120208

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60242180

Country of ref document: DE

Effective date: 20121109

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120831

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120829

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20150826

Year of fee payment: 14

Ref country code: IE

Payment date: 20150810

Year of fee payment: 14

Ref country code: DE

Payment date: 20150825

Year of fee payment: 14

Ref country code: ES

Payment date: 20150713

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20150629

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20150827

Year of fee payment: 14

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60242180

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20160829

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20170428

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170301

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160829

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160829

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160830

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20181126